APAC Solid Tumor Market

APAC Solid Tumor Market (2024 to 2029)

The Solid Tumor Market in the Asia Pacific is projected to rise at a promising CAGR during the forecast period.

Solid tumors are formed due to the collection of abnormal tissues that do not contain any cyst or liquid regions within. Solid tumors are of two types, i.e., benign (non-cancerous) and malignant (cancerous) in nature.

Some of the significant driving agents for this market's growth include increasing incidences of several cases of solid tumors. Due to an increase in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents, which drives the market. 

The high expense of cancer therapy, an increase in drug patent cliff, and the increasing size of non-proprietary therapeutic products are anticipated to be the growth hindering factors for the APAC Solid Tumor therapeutics market.

This research report has been segmented and sub-segmented into the following categories

APAC Solid Tumor Market Analysis By Disease

• Breast cancer     
• Lung cancer      
• Colorectal cancer
• Prostate cancer
• Cervical cancer
• Others    

APAC Solid Tumor Market Analysis By Drugs

• Carboplatin       
• Cisplatin  
• Gemcitabine      
• Paclitaxel
• Doxorubicin      
• Bevacizumab     
• Erlotinib  
• Sunitinib  
• Everolimus      
• Docetaxel       
• Abiraterone     
• Abiraterone acetate     
• Cabazitaxel

APAC Solid Tumor Market Analysis By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, Asia Pacific is a lucrative market and is expected to grow at a high CAGR during the forecast timeline. The Asia Pacific is the most lucrative market for the Solid Tumor market due to recent healthcare infrastructure improvements and expanding medical tourism in these regions. The region also accounts for a high cancer patient population, and increasing awareness and affordability of this region's people will contribute heavily towards the future growth of the market in the area.

With the Chinese government's hopeful plans for healthcare improvements, access to healthcare amenities and drugs is anticipated to grow in the coming decade, which could be a vital driver for the solid tumors market. However, pricing control in China and India could limit potential growth. In recent years, many efforts were made by the pricing and regulatory bodies in India and China to improve innovative drugs' access and affordability.

Major companies operating in the Asia Pacific Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

Recent Market Developments

• On June 02, 2019, Roche made a public statement that the combination of Tecentriq, Avastin, carboplatin, and paclitaxel showed positive results in the patients suffering from liver metastases.
• On December 02, 2019, two major companies, Innovent and Eli Lilly and Company, collectively launched their Tyvyt. The medicine works to restore the patient's tumor T-cell response. The result between the two companies provides patients with effective and protected treatment solutions to fight against cancer.